Live Chat

交易 BioNTech BNTX

出售
 購買

BioNTech實時圖表

5m 15m 30m 1h 4h 1d 1w

金融工具基礎知識

Weekly Search
Weekly
Daily
date 關閉 change 更改(%)： 開倉 高 低

Markets.com news

N/A
2024 Dec 10, 16:00

中文的文章

man writing inflation on line charts
Alvaro Ramos 2024 Aug 07, 16:00

No English Content Dependency

2024 Jul 31, 16:00

测试标题

Volkswagen shares drop on overnight profit warning
Georgy Istigechev 2024 Jul 10, 10:45

Volkswagen shares slide as firm mulls Brussels plant closure (ZH-TW)

聯絡方式

點差

0.9949

點差(%)

0.8754 %

槓桿

1:10

隔夜利息（買入）

-0.0597 %

隔夜利息（賣出）

-0.0292 %

貨幣

USD

交易時間

市場開放

星期二

14:31 - 20:59

星期一

14:31-20:59

星期三

14:31-20:59

星期四

14:31-20:59

星期五

14:31-20:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

27212888064

流通股份

239740000

收益日期（下一個）

0000-00-00

instr__dividend_date

2022-06-17

instr__ex_dividend_date

2022-06-02

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

每股盈餘

-2.01

了解有關此金融工具的詳細資訊

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

相關金融工具

資產
出售
購買
更改(%)：

立即交易

立即交易

立即交易

立即交易
查看所有金融工具
Trustpilot
Live Chat